Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005–2010

Smith, Sarah E.; Ershova, Julia; Vlasova, Natalia; Nikishova, Elena; Tarasova, Irina; Eliseev, Platon; Maryandyshev, Andrey O.; Shemyakin, Igor G.; Kurbatova, Ekaterina; Cegielski, J. Peter

doi:10.3201/eid2106.141907

i

Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005–2010

Supporting Files Public Domain

Jun 2015
By Smith, Sarah E. ; Ershova, Julia ; Vlasova, Natalia ; ...

File Language:

English

Details

Alternative Title:

Emerg Infect Dis
Personal Author:

Smith, Sarah E. ; Ershova, Julia ; Vlasova, Natalia ; Nikishova, Elena ; Tarasova, Irina ; Eliseev, Platon ; Maryandyshev, Andrey O. ; Shemyakin, Igor G. ; Kurbatova, Ekaterina ; Cegielski, J. Peter
Description:

Acquired resistance to antituberculosis drugs decreases effective treatment options and the likelihood of treatment success. We identified risk factors for acquisition of drug resistance during treatment for multidrug-resistant tuberculosis (MDR TB) and evaluated the effect on treatment outcomes. Data were collected prospectively from adults from Arkhangelsk Oblast, Russia, who had pulmonary MDR TB during 2005-2008. Acquisition of resistance to capreomycin and of extensively drug-resistant TB were more likely among patients who received <3 effective drugs than among patients who received >3 effective drugs (9.4% vs. 0% and 8.6% vs. 0.8%, respectively). Poor outcomes were more likely among patients with acquired capreomycin resistance (100% vs. 25.9%), acquired ofloxacin resistance (83.6% vs. 22.7%), or acquired extensive drug resistance (100% vs. 24.4%). To prevent acquired drug resistance and poor outcomes, baseline susceptibility to first- and second-line drugs should be determined quickly, and treatment should be adjusted to contain >3 effective drugs.
Subjects:

Adult Antitubercular Agents/Therapeutic Use Cohort Studies Drug Resistance, Multiple, Bacterial Female Humans Male Middle Aged Mycobacterium Tuberculosis/Drug Effects Research Risk Factors Treatment Outcome Young Adult
Source:

Emerg Infect Dis. 21(6):1002-1011.
Document Type:

Journal Article
Place as Subject:

Russia
Location:

Europe
Volume:

21
Issue:

6
Collection(s):

Emerging Infectious Diseases
Main Document Checksum:

urn:sha256:775522c403f73514641c7ba37c12a7e883225d19398e536ded215f0e5d5e9f77
Download URL:

https://stacks.cdc.gov/view/cdc/31541/cdc_31541_DS1.pdf
File Type:

[PDF - 2.09 MB ]

File Language:

English

ON THIS PAGE

Details Supporting Files

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.